S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
ASML’s Earnings Could Bring The Stock to New Highs
3 Computer Vision Stocks for Long-Term Gains From AI
Closing prices for crude oil, gold and other commodities
Undervalued UnitedHealth Group Won’t Be For Long
DocuSign and The Case for 66% Upside 
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
ASML’s Earnings Could Bring The Stock to New Highs
3 Computer Vision Stocks for Long-Term Gains From AI
Closing prices for crude oil, gold and other commodities
Undervalued UnitedHealth Group Won’t Be For Long
DocuSign and The Case for 66% Upside 
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
ASML’s Earnings Could Bring The Stock to New Highs
3 Computer Vision Stocks for Long-Term Gains From AI
Closing prices for crude oil, gold and other commodities
Undervalued UnitedHealth Group Won’t Be For Long
DocuSign and The Case for 66% Upside 
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
ASML’s Earnings Could Bring The Stock to New Highs
3 Computer Vision Stocks for Long-Term Gains From AI
Closing prices for crude oil, gold and other commodities
Undervalued UnitedHealth Group Won’t Be For Long
DocuSign and The Case for 66% Upside 

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Moderna, Inc. stock logo
MRNA
Moderna
$103.79
-0.1%
$100.03
$62.55
$156.75
$39.74B1.624.24 million shs2.16 million shs
Novavax, Inc. stock logo
NVAX
Novavax
$3.99
-3.2%
$4.70
$3.53
$11.36
$558.40M1.597.86 million shs3.70 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$25.68
-0.9%
$27.27
$25.61
$41.33
$145.41B0.6142.55 million shs28.85 million shs
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Moderna, Inc. stock logo
MRNA
Moderna
-1.22%-1.17%+0.01%+1.66%-33.89%
Novavax, Inc. stock logo
NVAX
Novavax
-3.74%-7.00%-22.12%-5.07%-55.02%
Pfizer Inc. stock logo
PFE
Pfizer
+0.15%-2.56%-7.30%-8.51%-37.12%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Moderna, Inc. stock logo
MRNA
Moderna
3.9954 of 5 stars
3.12.00.04.62.33.30.6
Novavax, Inc. stock logo
NVAX
Novavax
3.8498 of 5 stars
3.33.00.04.72.30.80.6
Pfizer Inc. stock logo
PFE
Pfizer
4.9912 of 5 stars
3.25.04.24.82.61.73.1

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Moderna, Inc. stock logo
MRNA
Moderna
2.24
Hold$126.4921.87% Upside
Novavax, Inc. stock logo
NVAX
Novavax
2.67
Moderate Buy$17.00326.07% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.35
Hold$36.8843.59% Upside

Current Analyst Ratings

Latest NVAX, PFE, and MRNA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/15/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
4/11/2024
Moderna, Inc. stock logo
MRNA
Moderna
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold
4/9/2024
Moderna, Inc. stock logo
MRNA
Moderna
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$125.00
4/1/2024
Moderna, Inc. stock logo
MRNA
Moderna
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
4/1/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
3/28/2024
Moderna, Inc. stock logo
MRNA
Moderna
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$125.00
3/28/2024
Moderna, Inc. stock logo
MRNA
Moderna
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold
3/22/2024
Pfizer Inc. stock logo
PFE
Pfizer
Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
3/1/2024
Novavax, Inc. stock logo
NVAX
Novavax
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$35.00 ➝ $19.00
3/1/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
2/26/2024
Moderna, Inc. stock logo
MRNA
Moderna
HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Reduce$75.00 ➝ $86.00
(Data available from 4/16/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Moderna, Inc. stock logo
MRNA
Moderna
$6.85B5.80N/AN/A$36.33 per share2.86
Novavax, Inc. stock logo
NVAX
Novavax
$983.71M0.57N/AN/A($6.04) per share-0.66
Pfizer Inc. stock logo
PFE
Pfizer
$58.50B2.49$2.96 per share8.69$15.81 per share1.62

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Moderna, Inc. stock logo
MRNA
Moderna
-$4.71B-$12.41N/AN/AN/A-68.84%-10.23%-7.70%5/2/2024 (Estimated)
Novavax, Inc. stock logo
NVAX
Novavax
-$545.06M-$5.53N/A49.88N/A-55.41%N/A-32.63%5/14/2024 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$2.12B$0.3671.339.301.163.62%10.88%4.91%5/1/2024 (Confirmed)

Latest NVAX, PFE, and MRNA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2024N/A
Pfizer Inc. stock logo
PFE
Pfizer
$0.57N/A-$0.57N/AN/AN/A  
2/28/2024Q4 2023
Novavax, Inc. stock logo
NVAX
Novavax
-$0.49-$1.44-$0.95-$1.44$310.96 million$291.34 million      
2/22/2024Q4 2023
Moderna, Inc. stock logo
MRNA
Moderna
-$0.78$0.55+$1.33$0.55$2.53 billion$2.80 billion    
1/30/202412/31/2023
Pfizer Inc. stock logo
PFE
Pfizer
-$0.19$0.10+$0.29$0.80$14.37 billion$14.25 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Novavax, Inc. stock logo
NVAX
Novavax
N/AN/AN/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.686.54%+2.57%466.67%15 Years

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Moderna, Inc. stock logo
MRNA
Moderna
0.04
3.42
3.36
Novavax, Inc. stock logo
NVAX
Novavax
N/A
0.70
0.67
Pfizer Inc. stock logo
PFE
Pfizer
0.69
0.91
0.69

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Novavax, Inc. stock logo
NVAX
Novavax
53.04%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
Moderna, Inc. stock logo
MRNA
Moderna
15.20%
Novavax, Inc. stock logo
NVAX
Novavax
0.90%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Moderna, Inc. stock logo
MRNA
Moderna
5,600382.88 million324.68 millionOptionable
Novavax, Inc. stock logo
NVAX
Novavax
1,543139.95 million138.69 millionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
88,0005.66 billion5.66 billionOptionable

NVAX, PFE, and MRNA Headlines

SourceHeadline
Pfizer Inc. (NYSE:PFE) Shares Bought by Allen Capital Group LLCPfizer Inc. (NYSE:PFE) Shares Bought by Allen Capital Group LLC
marketbeat.com - April 16 at 5:51 PM
Pfizers Doldrums, Just A Bad Case Of COVID-19?Pfizer's Doldrums, Just A Bad Case Of COVID-19?
seekingalpha.com - April 16 at 2:34 PM
Pfizer (NYSE:PFE) Stock Price Down 0.2%Pfizer (NYSE:PFE) Stock Price Down 0.2%
marketbeat.com - April 16 at 2:02 PM
Pfizers (PFE) Overweight Rating Reaffirmed at Cantor FitzgeraldPfizer's (PFE) Overweight Rating Reaffirmed at Cantor Fitzgerald
americanbankingnews.com - April 16 at 4:26 AM
Why the Market Dipped But Pfizer (PFE) Gained TodayWhy the Market Dipped But Pfizer (PFE) Gained Today
zacks.com - April 15 at 6:51 PM
Pfizer Eyeing Viking Therapeutics? A Scenario Among All The M&A TalkPfizer Eyeing Viking Therapeutics? A Scenario Among All The M&A Talk
seekingalpha.com - April 15 at 5:39 PM
Pfizer (NYSE:PFE) Trading Up 0.7%Pfizer (NYSE:PFE) Trading Up 0.7%
marketbeat.com - April 15 at 3:37 PM
A Closer Look at Pfizers Options Market DynamicsA Closer Look at Pfizer's Options Market Dynamics
benzinga.com - April 15 at 12:38 PM
Cullen Investment Group LTD. Takes Position in Pfizer Inc. (NYSE:PFE)Cullen Investment Group LTD. Takes Position in Pfizer Inc. (NYSE:PFE)
marketbeat.com - April 15 at 11:27 AM
Cantor Fitzgerald Reaffirms "Overweight" Rating for Pfizer (NYSE:PFE)Cantor Fitzgerald Reaffirms "Overweight" Rating for Pfizer (NYSE:PFE)
marketbeat.com - April 15 at 11:21 AM
Is Pfizer Stock a Buy?Is Pfizer Stock a Buy?
fool.com - April 15 at 8:45 AM
Pfizer’s Velsipity UK approval to raise competition in ulcerative colitis marketPfizer’s Velsipity UK approval to raise competition in ulcerative colitis market
biopharma-reporter.com - April 15 at 7:37 AM
Want $1,000 in Annual Dividend Income? Invest $13,200 in These Ultra-High-Yield Dividend Stocks.Want $1,000 in Annual Dividend Income? Invest $13,200 in These Ultra-High-Yield Dividend Stocks.
fool.com - April 15 at 4:53 AM
Conning Inc. Raises Stock Holdings in Pfizer Inc. (NYSE:PFE)Conning Inc. Raises Stock Holdings in Pfizer Inc. (NYSE:PFE)
marketbeat.com - April 14 at 3:45 PM
Pfizer (NYSE:PFE) Trading Down 0.8%Pfizer (NYSE:PFE) Trading Down 0.8%
americanbankingnews.com - April 14 at 3:12 AM
Lecap Asset Management Ltd. Invests $1.32 Million in Pfizer Inc. (NYSE:PFE)Lecap Asset Management Ltd. Invests $1.32 Million in Pfizer Inc. (NYSE:PFE)
marketbeat.com - April 13 at 8:17 PM
Pfizer wins pause on Modernas COVID-19 patent lawsuitPfizer wins pause on Moderna's COVID-19 patent lawsuit
reuters.com - April 13 at 7:22 PM
The Smartest Dividend Stocks to Buy With $400 Right NowThe Smartest Dividend Stocks to Buy With $400 Right Now
fool.com - April 13 at 5:47 AM
Pfizer Inc. (NYSE:PFE) to Post Q1 2025 Earnings of $0.59 Per Share, Zacks Research ForecastsPfizer Inc. (NYSE:PFE) to Post Q1 2025 Earnings of $0.59 Per Share, Zacks Research Forecasts
americanbankingnews.com - April 13 at 3:08 AM
Pfizer Inc. (NYSE:PFE) Stock Position Lessened by Xcel Wealth Management LLCPfizer Inc. (NYSE:PFE) Stock Position Lessened by Xcel Wealth Management LLC
marketbeat.com - April 12 at 7:27 PM
Pfizers Innovative Drug Pipeline Provides Ample Reason To Buy It HerePfizer's Innovative Drug Pipeline Provides Ample Reason To Buy It Here
seekingalpha.com - April 12 at 7:27 PM
Big Pharma: Investment BedrockBig Pharma: Investment Bedrock
finance.yahoo.com - April 12 at 7:27 PM
Pfizer’s 15-month fall: Will the stock ever recover?Pfizer’s 15-month fall: Will the stock ever recover?
kalkinemedia.com - April 12 at 2:26 PM
Pfizer (NYSE:PFE) Stock Price Down 0.8%Pfizer (NYSE:PFE) Stock Price Down 0.8%
marketbeat.com - April 12 at 2:02 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Moderna logo

Moderna

NASDAQ:MRNA
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Novavax logo

Novavax

NASDAQ:NVAX
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Pfizer logo

Pfizer

NYSE:PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.